MaaT Pharma (MAAT) Corporate presentation summary

Leadership in hemato-oncology and clinical progress

• Achieved all endpoints in the pivotal ARES trial for XervytegⓇ (MaaT013) in acute Graft-versus-Host Disease (aGvHD), with a GI-ORR of 62% and 1-year OS of 54%.

• XervytegⓇ (MaaT013) is under EMA re-examination, with a decision expected in September 2026.

• Early Access Program shows increasing international demand and real-world efficacy consistent with pivotal trial data.

• MaaT033 is in a pivotal Phase 2b trial (PHOEBUS) for allo-HSCT, with results expected in Q4 2028.

• MaaT034 is advancing as a first-in-class co-cultured candidate for immuno-oncology, targeting first-in-human studies in 2027.

Financial and commercial overview

• Cash position of €18.1 million as of March 31, 2026, with runway to November 2026.

• Commercial partnership with Clinigen for XervytegⓇ in Europe includes €10.5M upfront, €12M MAA milestone, up to €6M sales milestones, and mid-thirties royalties.

• European peak sales for XervytegⓇ estimated at €75–100M, with a total hemato-oncology market opportunity of ~€750M.

• Largest European cGMP facility for microbiome therapies, supporting scalable production.

Scientific platform and pipeline

• Proprietary full-ecosystem, donor-derived, and AI-powered co-cultured microbiome therapies.

• Integrated GMP production enables up to 11,000 treatable patients per year for XervytegⓇ and 6,000 for MaaT033.

• Pipeline includes late-stage and preclinical assets targeting hemato-oncology and immuno-oncology indications.

• MaaT034 demonstrates synergistic anti-tumor activity with anti-PD-1 in preclinical models.